Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs

Research output: Contribution to journalShort surveypeer-review


Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual disease and prevent leukemia relapse. Now in Cell Stem Cell, Cai et al. (2015) show that loss-of-function mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal hematopoietic cells through increased stress resistance.

Original languageEnglish (US)
Article number1816
Pages (from-to)129-131
Number of pages3
JournalCell Stem Cell
Issue number2
StatePublished - Aug 6 2015

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology


Dive into the research topics of 'Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs'. Together they form a unique fingerprint.

Cite this